Objectives: Altered linezolid pharmacokinetics (PK) in obese individuals has been hypothesized in previous studies. However, specific dosing recommendations for this population are still lacking. The main goal of this study was to evaluate PK/pharmacodynamic (PKPD) target attainment when using a 600 mg intravenous q12h linezolid dose against MRSA in obese patients with pneumonia.
Introduction
The increasing worldwide prevalence of obesity is a major burden on healthcare.
1,2 Obese individuals not only have a higher morbidity than their non-obese counterparts, 3, 4 but successful treatment may also be hampered by uncertainty in terms of correct drug dosing. Drug dosing in obese patients is generally considered off-label because in most cases obese patients are not included in clinical trials during drug development. Therefore, the dosing regimens on the label might not be suitable for treating obese patients.
Pathophysiological changes in obese patients can have a significant influence on drug distribution and elimination, thereby altering a drug's pharmacokinetic (PK) characteristics. [4] [5] [6] Consequently, overdosing or underdosing is likely to occur in this specific population. 3 This issue may of particular clinical relevance for drug treatments in which the effect of the drug is difficult to monitor, for example antibiotic treatments.
MRSA is a Gram-positive micro-organism that is resistant to most antibiotics. 7, 8 The increasing prevalence of MRSA is becoming a major therapeutic challenge in hospitals worldwide. 9, 10 Linezolid, the first antibacterial agent of the oxazolidinone group of antibiotics, is used to treat pneumonia and skin and soft tissue infections caused by Gram-positive bacteria, including MRSA. 11, 12 As a moderately lipophilic drug (log P " 0.9), linezolid is mainly metabolized in the liver and only 30% of the drug is renally eliminated. 13 Linezolid has a relatively low (31%) plasma protein binding, and its steady-state volume of distribution is 40-50 L, which approximates the total volume of water in a human body.
14 For linezolid treatment, the PK/pharmacodynamic (PK/PD) indices that strongly correlate with clinical eradication of the invading pathogen are the time the linezolid concentration remains above the MIC (T .MIC ) and the AUC/MIC ratio over 24 h. 9, 14 The current recommended dose of linezolid is 600 mg q12h via intravenous (iv) or oral administration. At the moment, there are no specific dosing recommendations for obese patients. Nevertheless, alterations of linezolid PK have been described in obese patients. 10, [15] [16] [17] [18] [19] [20] In two case reports and a small cohort study (n " 7), linezolid serum concentrations in obese patients were found to be lower than in normal-weight patients. 10, 15, 17 Furthermore, Bhalodi et al. 18 showed a positive association between the volume of distribution and body weight for moderately and morbidly (otherwise healthy) obese adults. This finding was confirmed in population PK studies of linezolid in normal-weight and obese patients. 16, 20 However, no information is available on the efficacy of linezolid in obese patients given 600 mg q12h dosing for the treatment of MRSA in this specific population.
Therefore, the goal of this study was to determine PKPD target attainment as a surrogate measure for linezolid efficacy in obese pneumonia patients with MRSA involvement. In this study we aimed: (i) to describe the PK variability of linezolid concentrations in a cohort of obese patients through the use of population PK modelling; (ii) to evaluate the influence of patient characteristics on the PTA against MRSA; and (iii) to evaluate the time course of target attainment within patients throughout therapy.
Patients and methods

Ethics
The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study protocol was reviewed and approved by the local institutional review boards of the participating centres (ClinicalTrials.gov Identifier: NCT01805284). Written informed consent was obtained from all patients prior to their enrolment in the study.
Study design and patients
This multicentre, open-label study of linezolid PK was conducted at the University Hospital of Larissa, the University Hospital of Ioannina and University Hospital Heraklion, Greece from 2014 to 2016. Patients were enrolled if they met all of the following inclusion criteria: (i) age !18 years; (ii) obese (BMI .35 kg/m 2 ); (iii) confirmed or clinically suspected hospital-, healthcare-or community-acquired pneumonia; (iv) confirmed involvement of MRSA in the infection; (v) admitted to an ICU; (vi) decision made to start treatment with linezolid therapy. Exclusion criteria were: (i) absence of an arterial line for blood sampling; (ii) anuria; (iii) pregnancy; (iv) need for renal replacement therapy; and (v) prior administration of more than one dose of iv linezolid.
Drug administration and sample collection
During the study participants received six 600 mg doses of iv linezolid q12h. All doses were administered via a 30 min infusion. Blood samples were collected before every drug administration, and at 0.5 (end of the infusion), 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, 10, 12 h after the start of the sixth dose. Blood samples were centrifuged within 30 min (4 C, 10 min, 1500 g) and transferred into a labelled polystyrene tube and frozen at #20 C until shipment. Samples were pooled and transported on dry ice from the study centres to the Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, where samples were then stored at #80 C until analysis.
Protein binding and sample measurement
Protein binding was determined for each patient using four plasma samples taken on three different days. Briefly, plasma samples were first incubated in a portable mini CO 2 incubator (N-BIOTECK, Korea) for 30 min (37 C, 10% CO 2 ). After the incubation, 400 lL of plasma was transferred into an Amicon V R Ultra-0.5 filter (0.5 mL, 30 kDa; Merck Millipore, Darmstadt, Germany) and centrifuged at 3200 g for 10 min at 37
C to obtain the ultrafiltrate (C unbound ). A separate plasma sample was incubated as a quality control to determine the total drug concentration (C total ). Protein binding (%) was calculated as 100 % [(1 -C unbound )/C total ]. The mean value of protein binding was reported for each patient.
Total and unbound linezolid concentrations were measured using a previously developed liquid chromatography-tandem mass spectrometry setup validated for the simultaneous quantification of b-lactam antibiotics and the oxazolidinone antibiotic linezolid in human plasma. 21 The method bias and precisions for linezolid were ,9.7% and ,11.2%, respectively. The lower limit of quantification of linezolid in plasma was 0.05 mg/L.
Population PK modelling Software
Non-linear mixed-effects modelling was performed in NONMEM V R version 7.3 (Icon Development Solutions, Ellicott City, MD, USA) employing firstorder conditional estimation (FOCE) with interaction, assisted by PerlSpeaks-NONMEM version 4.60 (Uppsala University, Uppsala, Sweden) through the Pirana workbench version 2.9.6 (Pirana Software). Data processing, simulations and plotting were carried out in R V R 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).
Model development
The population model was developed in a stepwise manner with the use of a log-transform-both-sides approach. Different structural models such as one-and two-compartmental models with linear and/or non-linear eliminations were tested. Inter-individual variability (IIV) and inter-occasion variability (IOV) were assumed to follow a log-normal distribution. The additive error model in the log domain was used throughout the entire process. All PK parameters were allometrically scaled to a total body weight of 70 kg. This means that the allometric exponent was fixed at 1.0 for all volume terms and 0.75 for all clearance terms. Covariates were screened by applying a stepwise forward addition (P , 0.05) and backward elimination (P , 0.01) procedure. Covariates tested were: age, sex, severity of sepsis episode (sepsis, severe sepsis and septic shock), creatinine clearance estimated by the Cockroft-Gault formula, 22 serum albumin, alanine transaminase, aspartate aminotransferase and total bilirubin.
Model selection and evaluation
Model comparison was guided by changes in the objective function value (OFV) between nested models (with a decrease .3.84 points being statistically significant for the inclusion of a single parameter), the Akaike information criterion between non-nested models, the condition number, the Xie et al.
relative standard error (RSE) of the parameter estimates and goodness-offit plots. 23, 24 The final PK model was evaluated using: (i) the visual predictive check (VPC) method (1000 simulations); 25 (ii) the normalized prediction distribution errors (NPDE); 26 and (iii) the sampling importance resampling (SIR) procedure for the assessment of parameter uncertainty. 27 
Prediction of PK/PD target attainment
The PK/PD index of AUC/MIC .100 and T .MIC of 100% were used to evaluate the linezolid treatment efficacy in the study patients. 28 In order to evaluate the observed target attainment, the AUC/MIC and T .MIC values were derived from the post-hoc PK parameter estimates for each patient at the time intervals 0-24, 24-48 and 48-72 h. The MIC of 4 mg/L was chosen because this concentration is considered as the linezolid-susceptible breakpoint for most Staphylococcus aureus isolates including MRSA (from the EUCAST website). 29 The PTA was stratified according to patient characteristics to evaluate potential associations.
Monte Carlo simulation
The final population PK model was used to conduct Monte Carlo simulations with the dosage regimen of 600 mg iv linezolid q12h for 3 days. The simulation was performed from 0 to 72 h in two scenarios: (i) 10000 virtual subjects with a fixed age of 60 years (median observed age in this cohort), and weight levels sampled randomly from a uniform distribution ranging from 50 to 160 kg; and (ii) 10000 virtual subjects with a fixed weight of 125 kg (median observed weight), and age values sampled randomly from a uniform distribution ranging from 30 to 85 years. The PTA for MIC values (1, 2 and 4 mg/L) up to the linezolid-susceptible breakpoint for MRSA was calculated for the periods 0-24, 24-48 and 48-72 h. According to the MIC distribution of MRSA for linezolid from the EUCAST MIC database (https://mic. eucast.org/Eucast2/regShow.jsp? Id"13366), the MICs of 1, 2 and 4 mg/L represent 1.40%, 54.08%, 44.46%, and in total 99.88% of the distribution. The cumulative fraction of response (CFR) that accounted for the selected MIC distribution was computed to further qualify linezolid target attainment in patient populations. In all scenarios, the following PKPD targets were used: 100% T .MIC , AUC/MIC . 100, and a combination of AUC/MIC . 100 and 100% T .MIC .
Results
Patient characteristics
A total of nine males and six females were included in the study. All patients completed the study. Recruitment of MRSA-positive, obese patients with pneumonia proved to be problematic. Moreover, linezolid is frequently used empirically in patients with an overt risk profile for MRSA involvement. Therefore, we decided to also include patients who were MRSA negative. We consider this as a minor protocol violation as we expect no influence on the PK profiling. Consequently, only two of the included patients were MRSA positive. A summary of the demographic and clinical characteristics for the included patients is shown in Table 1 .
Population PK analysis
A two-compartment model with linear elimination adequately described the linezolid concentrations. An additional IIV term on the residual error variance significantly improved the model fit (drop in OFV of 37.1) and was therefore retained in the model. This term allows for the residual error to vary between individuals. Implementation of IOV on PK parameters was tested and was found to be statistically significant for clearance (drop in OFV of 31.1). In addition to the weight effect, we found a linear age effect on clearance (drop in OFV of 9.9). The final linezolid population PK model is summarized in equations (1-4):
where CL is the linezolid clearance, h age is an age effect parameter on CL, V c is the linezolid central volume of distribution, Q is the intercompartmental linezolid clearance, V p is the linezolid peripheral volume of distribution, h is a population estimate, g is the IIV and j is the IOV. The parameter estimates and associated standard errors for the final model are shown in Table 2 . The goodness-of-fit plots shown in Figure 1 suggest an overall good fit of the model to the data. The VPC and the histogram of the NPDEs used to internally validate the final model are provided in Figures S1 and S2 , available as Supplementary data at JAC Online).
Prediction of PK/PD target attainment
The predicted AUC/MIC and T .MIC values for each patient at days 1, 2 and 3, together with the covariates of interest, are listed in Table 3 . In addition to the PKPD indices which were derived from total concentrations, as recommended in literature, 11, 28 Figure S3 shows AUC/MIC and T .MIC as a function of the patient characteristics (i.e. weight and age). 
Monte Carlo simulation
The indices T .MIC , AUC/MIC and a combination of them have all been used frequently in previous linezolid PKPD studies. 4, 11 It is reported that for linezolid treatment T .MIC and AUC/MIC were Xie et al.
highly correlated and performed similarly in terms of clinical outcomes. 28 Herein, we mainly focused on the 100% T .MIC target as linezolid is considered a time-dependent killing antibiotic especially against S. aureus. 30 The estimated PTAs and CFRs of 100% T .MIC versus weight and age for the three days of treatment against different MIC values are shown in Figure 2 . The estimated PTAs and CFRs versus weight and age for the AUC/MIC . 100 and combined 100% T .MIC and AUC/MIC . 100 targets are shown in Figures S4  and S5 .
Our PKPD simulations show that patients with high body weights are at a higher risk of not attaining the PKPD targets. The CFR for patients weighing 85 kg (the lowest observed weight) is An additive error model in the log-transformed domain was used to characterize the residual unexplained variability, which approximates to a proportional error in the normal domain. 27.3% at steady-state, and the probability drops to 19.2% for patients weighing 160 kg (the highest observed weight). When the target of AUC/MIC . 100 is considered, the weight effect on CFR is much more significant, with a 3.5-fold drop in probability observed. On the contrary, from the bottom panel in Figure 2 it can be seen that the PKPD target attainment is considerably higher in elderly patients. For patients 30 years old (the lowest observed age), the CFR is extremely low (2.8%), even at steady-state. The target attainment rate rises to 98.7% for 85-year-old patients (the highest observed age). In all studied scenarios, the PTAs are quite low (,60%) even at the lowest MIC (1 mg/L) except for the elderly patients (!65 years), regardless of the PKPD indices used.
Discussion
This study aimed to address the question of whether a standard 600 mg q12h dosing regimen is efficacious for the treatment of MRSA in obese patients with pneumonia using linezolid PKPD target attainment as a surrogate marker. Our study showed that body weight and age significantly affect linezolid PK. Moreover, these patient characteristics have a substantial influence on the probability of attaining PKPD indices associated with therapeutic success. The PK behaviour of linezolid has been studied before in healthy volunteers and obese patients. Abe et al. 20 and Minichmayr et al. 31 showed, in elderly patients and critically ill patients, respectively, that linezolid clearance decreases with age. In contrast, in a healthy volunteer study, Sisson et al. 32 showed no influence of age on clearance. Our results confirm that for obese patients linezolid clearance decreases with age from a value of 15.54 L/h for 30-year-old patients to 1.35 L/h in 85-year-old patients. By incorporating a size correction into our model based on allometric theory, 33 we ascertained that our model aligns with earlier work where it was shown that linezolid PK are influenced by a patient's body weight. 16, 19, 20, 31 Although creatinine clearance was previously shown to influence linezolid clearance, 19, 31 it was not retained as a covariate in our model. This was most likely because the majority of patients in our study had mild to moderate renal failure and renal clearance only accounts for 30% of total drug elimination. Xie et al.
It was previously shown that PTA against pathogens with a linezolid MIC of 4 mg/L is low in normal-weight and obese patients. Cojutti et al. 19 found a PTA of ,10% in overweight and obese patients following a 600 mg q12h dosing regimen of linezolid. At the same time, Minichmayr et al. 31 and Yang et al. 34 found a PTA of near zero in normal-weight healthy volunteers. Our findings in obese patients are in line with these previous findings in both normal-weight and obese patients. Through PKPD simulations we showed that, depending on the PKPD index, the PTA of typical obese patients (weighing 125 kg and 60 years old) with a linezolid MIC of 4 mg/L is 0 on day 1 and between 1.03% and 11.88% on day 3 of treatment.
In contrast to these findings, Cojutti et al. 19 reported a high CFR (.80%) against MRSA strains in overweight and obese patients. However, in their analysis Cojutti et al. used an MIC distribution (0.12-2 mg/L, MIC 90 " 1 mg/L) of staphylococci from a local surveillance programme. In line with these findings, Puzniak et al. 35 found a high weight-independent clinical success rate (86.2%) against complicated skin and skin structure infections and nosocomial pneumonia caused by MRSA. However, similar to the work by Cojutti et al., 19 most patients (+90%) in the study by Puzniak et al. 35 had an MIC 1 mg/L. The MRSA MIC distribution for linezolid from the EUCAST MIC database, as used in this study, is significantly different (range 1-4 mg/L, with the MIC 90 being 4 mg/L), leading to substantially lower CFRs. We feel that, based on the high prevalence of MRSA with MICs of 2 and 4 mg/L (in total 98.48% of the MIC distribution), the approach by Cojutti et al. 19 might falsely overestimate the CFR against MRSA.
When considering our results, the reader should appreciate that our study has some limitations. First, although plasma PK was frequently sampled, the population PK modelling and covariate screening was based on data from only 15 obese patients. This could have prevented the inclusion of more subtle covariate relationships in our model and might have affected the accuracy of the estimate of IIV terms. Second, due to difficulties in including patients with a documented MRSA infection we were not able to study the influence of MRSA infection on the PK of linezolid and the ensuing effect on PTA. Third, we simulated target attainment for the first 3 days of treatment, whereas it was previously shown that the average PKPD target attainment (e.g. across the first 7 days of therapy) was correlated to clinical cure. 28 As such, target attainment reported here might falsely under-or overestimate the probability for clinical cure. Finally, simulated PTAs for normal-weight subjects relied on extrapolation from our study population via allometric scaling. Although our extrapolated PTAs are in good agreement with previous reports in normal-weight subjects, our data did not allow us to formally test allometric scaling and the reported results in normal-weight subjects should be interpreted taking into account this uncertainty.
In conclusion, through population PK modelling and PKPD simulations we demonstrated that a 600 mg q12h linezolid dosing regimen is unlikely to be efficacious against MRSA infections in obese patients with pneumonia. We feel that our results, in combination with earlier reports on low target attainment against MRSA in normal-weight and obese patients, provide sufficient evidence to advise against standard linezolid dosing for the treatment of MRSA in obese patients.
